Protalix BioTherapeutics Issues 2025 Letter to Stockholders - Stock Titan

Protalix BioTherapeutics, Inc. shares accomplishments in 2024, including EMA validation for pegunigalsidase alfa dosing, phase I trial results for PRX-115, and repayment of convertible notes. The company looks forward to advancing PRX-115 and pipeline developments in 2025.


Related News

Protalix BioTherapeutics Issues 2025 Letter to Stockholders - Stock Titan

Protalix BioTherapeutics, Inc. shares accomplishments in 2024, including EMA validation for pegunigalsidase alfa dosing, phase I trial results for PRX-115, and repayment of convertible notes. The company looks forward to advancing PRX-115 and pipeline developments in 2025.

© Copyright 2024. All Rights Reserved by MedPath